JOA - 2026-11-02 - Journal Article
A Randomized Controlled Trial Examining the Effects of Extended Oral Tranexamic Acid on Postoperative Pain and Range of Motion Following Total Knee Arthroplasty.
Grosso MJ, Panek G, Weinz C, Hahn AK, Bauer JA
Topics
Key Takeaway
Extended oral TXA (1.95g daily POD1–3) added to standard IV TXA showed no significant difference in VAS pain scores at any time point through 12 weeks compared to placebo following primary TKA.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This double-blind RCT asked whether extended oral TXA (1.95g/day POD1–3) added to standard perioperative IV TXA (1g pre-incision and postoperatively) improves pain, ROM, opioid consumption, or ambulation after primary TKA. 86 patients were randomized to EOTXA (n=43) or placebo, with VAS pain as the primary outcome. No significant differences were found at any time point from POD1 through 12 weeks, nor in any secondary outcome (all P>0.10).
Key Limitation
The 12-week follow-up captures only early recovery and cannot address whether EOTXA influences longer-term outcomes such as chronic pain, stiffness, or patient-reported function at one year.
Original Abstract
BACKGROUND
The implementation of perioperative intravenous tranexamic acid (TXA) protocols in total knee arthroplasty (TKA) has led to improved outcomes related to decreased blood loss and decreased transfusion rates. A recent randomized controlled trial (RCT) demonstrated that there may be additional benefits to extended oral TXA (EOTXA) for improving pain and function in the early postoperative period. In this double-blind RCT, we examined the effects of EOTXA following primary TKA on postoperative pain, range of motion (ROM), opioid usage, and ambulation status.
METHODS
There were 86 patients undergoing primary total knee arthroplasty randomized to two groups: EOTXA versus placebo. All patients received one gram of intravenous TXA prior to incision and in the postoperative recovery area. Patients in the EOTXA group (n = 43) received 1.95 grams of oral TXA daily from postoperative day one through POD three. The primary outcome in this study was the visual analog scale (VAS) pain score in the three-month postoperative period. The secondary outcomes included ROM, ambulation status (assistive device usage), and opioid consumption.
RESULTS
There was no statistically significant difference in VAS pain scores at any time point: POD one Placebo 4.7 versus EOTXA 5.4 (P = 0.16); POD two 4.1 versus 4.4 (P = 0.33); POD three 3.7 versus 4.0 (P = 0.49); POD7 3.6 versus 3.7 (P = 0.66); two weeks 3.0 versus 2.8 (P = 0.63); six weeks 2.2 versus 1.8 (P = 0.22); and 12 weeks 1.2 versus 1.1 (P = 0.86). In addition, there were no significant differences in ROM, daily opioid consumption, and ambulation status at two, six, and 12 weeks postoperatively (P > 0.10).
CONCLUSIONS
In the largest RCT to date, this study found no significant difference in pain scores, opioid consumption, functional outcomes, or ambulation status with the addition of extended oral TXA following primary TKA. Based on these results, broad utilization of this protocol in primary TKA may not be warranted.